File(s) not publicly available

Developing a nontypeable Haemophilus influenzae (NTHi) vaccine

journal contribution
posted on 06.12.2017, 00:00 by J Poolman, L Bakaletz, A Cripps, P Denoel, A Forsgren, Jennelle Kyd, Y Lobet
There is a current high demand for nontypable Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic composition. We will present a summary of NTHi vaccine development, describing research efforts from SmithKline Beecham and other laboratories. Currently, major (P1, P2, P4, P5) and minor (P6, D15, TbpA/B, …) outer membrane proteins, LPS, adhesins (HMW, Hia, pili, P5) are being studied. Preclinical results with LPD, P5 (LB1) and OMP26 from our laboratories will be described including the use of animal models of otitis and lung infection.

Funding

Category 1 - Australian Competitive Grants (this includes ARC, NHMRC)

History

Volume

19

Start Page

108

End Page

115

Number of Pages

8

eISSN

1873-2518

ISSN

0264-410X

Location

United Kingdom

Publisher

Elsevier Ltd

Language

en-aus

Peer Reviewed

Yes

Open Access

No

External Author Affiliations

Biological Division; Lunds universitet; Ohio University; University of Canberra;

Era Eligible

No

Journal

Vaccine.